drugset / Trial / NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Timeline
- Start
- 2023-10-22
- Primary completion
- 2027-08-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Comparator | Lenalidomide | Other / unclassified | — | Oral |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |